COVID-19-associated heart failure: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
 
(219 intermediate revisions by 9 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}
{{SI}}
{{Main article|COVID-19}}
'''For COVID-19 frequently asked inpatient questions, click [[COVID-19 frequently asked inpatient questions|here]]'''<br>
'''For COVID-19 frequently asked outpatient questions, click [[COVID-19 frequently asked outpatient questions|here]]'''<br>
{{CMG}}; {{AE}}{{Mitra}}{{MC}}


{{CMG}}; {{AE}}
{{SK}} [[Novel coronavirus]], [[COVID-19]], [[Wuhan coronavirus]], [[coronavirus disease-19]], [[coronavirus disease 2019]], [[SARS-CoV-2]], [[2019-nCoV]], [[2019 novel coronavirus]], [[heart failure]], [[acute heart failure]], de Novo [[acute heart failure]], [[chronic heart failure]], [[acute decompensated heart failure]], HFrEF, HFpEF, heart failure with reduced ejection fraction, heart failure with a preserved ejection fraction


{{SK}}
==Overview==
Both de novo [[acute heart failure]] and acute decompensation of [[chronic heart failure]] can occur in [[patients]] with [[COVID-19]]. [[Patients]] with [[chronic heart failure]] may be at higher risk of developing severe [[COVID-19]] infection due to advanced age and the presence of multiple [[Comorbidity|comorbidities]].


==Overview==
==Historical perspective==


*Patients with chronic heart failure (HF) may be at higher risk of developing severe COVID-19 infection due to the advanced age and the presence of multiple comorbidities.
*In late December 2019, the [[novel coronavirus]], [[SARS-CoV-2]], originated in Wuhan, China. <ref name="urlWHO | Pneumonia of unknown cause – China">{{cite web |url=https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ |title=WHO &#124; Pneumonia of unknown cause – China |format= |work= |accessdate=}}</ref>
*Both de novo acute heart failure and acute decompensation of chronic heart failure can occur in patients with COVID-19.
*The World Health Organization(WHO) declared the outbreak a Public Health Emergency of International Concern On January 30, 2020, <ref name="urlStatement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)">{{cite web |url=https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) |title=Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) |format= |work= |accessdate=}}</ref> and a [[pandemic]] on March 12, 2020. <ref name="urlWHO Director-Generals opening remarks at the media briefing on COVID-19 - 11 March 2020">{{cite web |url=https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 |title=WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 |format= |work= |accessdate=}}</ref>
*On March 27, 2020, Inciardi et al. reported the first case of acute myopericarditis complicated by [[heart failure]] in an otherwise healthy 53-year-old woman one week after the onset of [[symptoms]] of COVID-19. <ref name="pmid32219357">{{cite journal |vauthors=Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M |title=Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) |journal=JAMA Cardiol |volume= |issue= |pages= |date=March 2020 |pmid=32219357 |doi=10.1001/jamacardio.2020.1096 |url=}}</ref>


==Classification==
==Classification==
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].


OR
*[[Heart Failure]] ([[(HF)|HF)]] during [[COVID-19]] infection may be classified similarly to [[heart failure]] from other causes.
* In general, [[heart failure]] can be classified based on:
**'''The pathophysiology of [[heart failure]]''':
***[[Systolic heart failure|Systolic HF]] vs [[Diastolic heart failure|diastolic HF]]
***[[Left sided heart failure|Left-sided HF]] vs [[Right-sided heart failure|right-sided HF]]
**'''The duration of [[symptoms]]''':
***[[Acute Heart Failure|Acute HF]] ([[Acute heart failure|AHF]]) vs [[Chronic heart failure|chronic HF]] ([[Congestive heart failure|CHF]])
**'''The underlying physiology based on [[left ventricular ejection fraction (LVEF)]]:'''
***[[Heart failure with reduced ejection fraction]] [[(HFrEF)]] vs [[heart failure with mid-range ejection fraction]] [[(HFmrEF)]] and [[heart failure with preserved ejection fraction]] [[(HFpEF)]]
**'''The severity of [[heart failure]]''' (i.e., the [[New York Heart Association Class]] I-IV)
**'''The stage of congestive heart failure''' (i.e., [[AHA Class A, B, C, D]])


[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3].
*[[Acute heart failure]] has two forms:
[Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
**Newly-arisen (“de novo”) acute heart failure
**Acutely decompensated chronic heart failure (ADCHF)


OR
[[File:Fig1.COVID-19-associated heart failure.jpg]]
 
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
 
OR
 
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
 
OR
 
The staging of [malignancy name] is based on the [staging system].
 
OR
 
There is no established system for the staging of [malignancy name].


==Pathophysiology==
==Pathophysiology==


Presumed pathophysiologic mechanisms for the development of new or worsening heart failure in patients with COVID-19 include:<ref name="pmid32219357">{{Cite pmid|32219357}}</ref> <ref name="pmid32360242">{{Cite pmid|32360242}}</ref> <ref name="pmid32186331">{{Cite pmid|32186331}}</ref> <ref name="pmid30625066">{{Cite pmid|30625066}}</ref> <ref name="pmid32140732">{{Cite pmid|32140732}}</ref>
*Presumed pathophysiologic mechanisms for the development of new or [[Congestive heart failure|decompensated heart failure]] in [[patients]] with [[COVID-19]] include:<ref name="pmid322193572">{{cite journal| author=Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D | display-authors=etal| title=Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). | journal=JAMA Cardiol | year= 2020 | volume=  | issue=  | pages=  | pmid=32219357 | doi=10.1001/jamacardio.2020.1096 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32219357 }}</ref> <ref name="pmid323602422">{{cite journal| author=Mehra MR, Ruschitzka F| title=COVID-19 Illness and Heart Failure: A Missing Link? | journal=JACC Heart Fail | year= 2020 | volume= 8 | issue= 6 | pages= 512-514 | pmid=32360242 | doi=10.1016/j.jchf.2020.03.004 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32360242 }}</ref> <ref name="pmid321863312">{{cite journal| author=Xiong TY, Redwood S, Prendergast B, Chen M| title=Coronaviruses and the cardiovascular system: acute and long-term implications. | journal=Eur Heart J | year= 2020 | volume= 41 | issue= 19 | pages= 1798-1800 | pmid=32186331 | doi=10.1093/eurheartj/ehaa231 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32186331 }}</ref> <ref name="pmid306250662">{{cite journal| author=Musher DM, Abers MS, Corrales-Medina VF| title=Acute Infection and Myocardial Infarction. | journal=N Engl J Med | year= 2019 | volume= 380 | issue= 2 | pages= 171-176 | pmid=30625066 | doi=10.1056/NEJMra1808137 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30625066 }}</ref> <ref name="pmid321407322">{{cite journal| author=Chen C, Zhou Y, Wang DW| title=SARS-CoV-2: a potential novel etiology of fulminant myocarditis. | journal=Herz | year= 2020 | volume= 45 | issue= 3 | pages= 230-232 | pmid=32140732 | doi=10.1007/s00059-020-04909-z | pmc=7080076 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32140732 }}</ref>
      
      
**Acute exacerbation of chronic heart failure
**Acute exacerbation of [[chronic heart failure]] caused by precipitating factors
**Acute myocardial injury (which in turn can be caused by several mechanisms)
**[[Acute myocardial injury]] (which in turn can be caused by several mechanisms)
**Stress cardiomyopathy (i.e., Takotsubo cardiomyopathy)
**[[Stress cardiomyopathy]] (i.e., [[Takotsubo cardiomyopathy]]) <ref name="pmid32644140">{{cite journal |vauthors=Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, Nowacki AS, Shah R, Khubber S, Kanaa'N A, Hedrick DP, Sleik KM, Mehta N, Chung MK, Khot UN, Kapadia SR, Puri R, Reed GW |title=Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic |journal=JAMA Netw Open |volume=3 |issue=7 |pages=e2014780 |date=July 2020 |pmid=32644140 |pmc=7348683 |doi=10.1001/jamanetworkopen.2020.14780 |url=}}</ref> <ref name="pmid32363351">{{cite journal |vauthors=Minhas AS, Scheel P, Garibaldi B, Liu G, Horton M, Jennings M, Jones SR, Michos ED, Hays AG |title=Takotsubo Syndrome in the Setting of COVID-19 Infection |journal=JACC Case Rep |volume= |issue= |pages= |date=May 2020 |pmid=32363351 |pmc=7194596 |doi=10.1016/j.jaccas.2020.04.023 |url=}}</ref>
**Impaired myocardial relaxation resulting in diastolic dysfunction [i.e., Heart failure with preserved ejection fraction (HFpEF)]
**Impaired myocardial relaxation resulting in [[diastolic dysfunction]] [i.e., [[Heart failure with preserved ejection fraction (HFpEF)]] ]
**Right-sided heart failure, secondary to pulmonary hypertension caused by hypoxia and acute respiratory distress syndrome (ARDS)
**Right-sided heart failure, secondary to [[pulmonary hypertension]] caused by hypoxia and [[acute respiratory distress syndrome]] (ARDS)


==Causes==
Disease name] may be caused by [cause1], [cause2], or [cause3].


OR


Common causes of [disease] include [cause1], [cause2], and [cause3].
[[File:Fig2.COVID-19-associated heart failure.jpg]]


OR


The most common cause of [disease name] is [cause 1]. Less common causes of [disease name] include [cause 2], [cause 3], and [cause 4].


OR
{| class="wikitable"
|+
|-
| align="center" style="background: #4479BA; color: #FFFFFF |'''Common Precipitating factors in COVID-19 patients'''
|-
|'''[[Cardiac]]'''
|-
|
* [[Myocardial ischemia]]
|-
|
* [[Arrhythmias]] (tachy- or brady Arrhythmias)
|-
|
* [[Stress-induced cardiomyopathy]] [[(Takutsobu Cardiomyopathy)]]
|-
|
*[[Myocardial injury]]
|-
|
*[[Myocarditis]]
|-
|-
|'''Pressure overload '''
|-
|
*[[Hypertensive urgency]] or emergency
|-
|-
|'''Volume overload '''
|-
|
* Decreased compliance with [[diuretics]]
|-
|
* Renal dysfunction
|-
|-
|'''Pulmonary'''
|-
|
*[[Acute Pulmonary embolism]]
|-
|
*[[Hypoxia]]
|-
|
*[[Pneumonia]]
|-
|
*[[Acute respiratory distress syndrome]]
|-
|-
|'''Increased systemic metabolic demand '''
|-
|
*[[Fever]]
|-
|
*[[Sepsis]]
|-
|-
|'''Iatrogenic'''
|-
|
*Cardiovascular toxicity of medications
|-
|
*Aggressive fluid resuscitation
|-
|-
|'''Others'''
|-
|
*Anemia
|-
|
*Decreased compliance with [[heart failure]] medications
|}
{|
|-
|}


The cause of [disease name] has not been identified. To review risk factors for the development of [disease name], click [[Pericarditis causes#Overview|here]].
==Causes==


==Differentiating ((Page name)) from other Diseases==
Acute [[heart failure]] in [[COVID-19]] patients may be caused by: <ref name="pmid32644140">{{cite journal |vauthors=Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, Nowacki AS, Shah R, Khubber S, Kanaa'N A, Hedrick DP, Sleik KM, Mehta N, Chung MK, Khot UN, Kapadia SR, Puri R, Reed GW |title=Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic |journal=JAMA Netw Open |volume=3 |issue=7 |pages=e2014780 |date=July 2020 |pmid=32644140 |pmc=7348683 |doi=10.1001/jamanetworkopen.2020.14780 |url=}}</ref> <ref name="pmid32363351">{{cite journal |vauthors=Minhas AS, Scheel P, Garibaldi B, Liu G, Horton M, Jennings M, Jones SR, Michos ED, Hays AG |title=Takotsubo Syndrome in the Setting of COVID-19 Infection |journal=JACC Case Rep |volume= |issue= |pages= |date=May 2020 |pmid=32363351 |pmc=7194596 |doi=10.1016/j.jaccas.2020.04.023 |url=}}</ref>
[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
*[[Acute myocardial injury]]
*[[Acute coronary syndromes]]
*[[Myocarditis]]
*[[Hypertensive crisis]]
*[[Arrhythmias]]: Tachycardia or severe bradycardia
*[[Stress-induced cardiomyopathy]] ([[Takotsubo cardiomyopathy]])
*Circulatory failure:
**[[Acute pulmonary embolism]]
**[[Pericardial tamponade]]
*[[Iatrogenic]]


OR
==Differentiating COVID-19 associated heart failure from other Diseases==


[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
* For further information about the differential diagnosis, click [[Differentiating COVID-associated heart failure from other Diseases|here]].


==Epidemiology and Demographics==
==Epidemiology and Demographics==
The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*Data on [[incidence]] on acute [[heart failure]] in [[COVID-19]] patients is limited.  
 
*In one study, [[acute heart failure]] was seen in 4.1% of patients with [[acute cardiac injury]]. <ref name="urlAssociation of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China | Global Health | JAMA Cardiology | JAMA Network">{{cite web |url=+https://doi.org/10.1001/jamacardio.2020.0950 |title=Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China &#124; Global Health &#124; JAMA Cardiology &#124; JAMA Network |format= |work= |accessdate=}}</ref>
OR
*In a retrospective study on 191 [[COVID-19]] patients in Wuhan, China, the incidence of [[heart failure]] was 23% (52% in non-survivors vs 12% in survivors). <ref name="pmid32171076">{{cite journal |vauthors=Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B |title=Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study |journal=Lancet |volume=395 |issue=10229 |pages=1054–1062 |date=March 2020 |pmid=32171076 |pmc=7270627 |doi=10.1016/S0140-6736(20)30566-3 |url=}}</ref>
 
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
 
OR
 
In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.


=== Age ===
*[[Heart failure]] commonly affects older patients with [[COVID-19]].


=== Gender===
*There is no data on gender predilection to [[heart failure]] in [[COVID-19]].


Patients of all age groups may develop [disease name].
=== Race===
 
*There is no data on racial predilection to [[heart failure]] [[COVID-19]].
OR
 
The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
 
OR
 
[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
 
OR
 
[Chronic disease name] is usually first diagnosed among [age group].
 
OR
 
[Acute disease name] commonly affects [age group].
 
 
 
There is no racial predilection to [disease name].
 
OR
 
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
 
 
 
[Disease name] affects men and women equally.
 
OR
 
[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
 
 
 
The majority of [disease name] cases are reported in [geographical region].
 
OR
 
[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].


==Risk Factors==
==Risk Factors==
There are no established risk factors for [disease name].


OR
*The most common [[risk factors]] in the development of acute [[heart failure]] in [[COVID-19]] patients are:
**Older age
**Pre-existing [[congestive heart failure]]
**Well-established [[risk factors]] of [[heart failure]], including:
***[[Hypertension]]
***[[Coronary artery disease]]
***[[Diabetes]]
***Smoking


The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
To read more on the [[risk factors]] of [[congestive heart failure]], [[Congestive heart failure risk factors|click here]].<br />
 
OR
 
Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
 
OR
 
Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.


==Screening==
==Screening==
There is insufficient evidence to recommend routine screening for [disease/malignancy].
*There is insufficient evidence to recommend routine screening for [[heart failure]] in [[COVID-19]] patients.
 
*Routine measurement of [[natriuretic peptides]] and/or cardiac troponins has not been recommended in the absence of a high index of suspicion for [[heart failure]] on the clinical grounds.
OR
 
According to the [guideline name], screening for [disease name] is not recommended.
 
OR
 
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
*[[COVID-19]] patients with [[chronic heart failure]] are more likely to develop severe forms of the disease.
 
*[[COVID-19]] patients who develop [[acute heart failure]] (either de novo acute heart failure or acute decompensated heart failure) generally have worse outcomes.
OR
*[[Acute heart failure]] in [[COVID-19]] may progress to [[cardiogenic shock]].  
 
 
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
 
OR
 
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
 
==Diagnosis==
==Diagnosis==
===Diagnostic Study of Choice===
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
There are no established criteria for the diagnosis of [disease name].


===History and Symptoms===
===History and Symptoms===
The majority of patients with [disease name] are asymptomatic.


OR
*The most common symptoms of [[acute heart failure]] in [[COVID-19]] patients are:
**New or worsening [[dyspnea]]: may overlap with dyspnea caused by concomitant respiratory involvement and [[acute respiratory distress syndrome]] due to [[COVID-19]]
**[[Orthopnea]]
**[[Paroxysmal nocturnal dyspnea]]
**[[Peripheral edema]]
**Fatigue
**[[Palpitations]]


The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].
*Other common symptoms include:
**[[Confusion]] and [[altered mental status]]
**Cool extremities
**[[Cyanosis ]]
**[[Dizziness]]
**[[Syncope]]
**[[Hemoptysis]]


===Physical Examination===
===Physical Examination===
Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].
OR
Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].
OR


The presence of [finding(s)] on physical examination is diagnostic of [disease name].
*Physical examination of patients with [[acute heart failure]] is usually remarkable for:
 
**[[Tachycardia]]
OR
**[[Crackles]] on lung auscultation
 
**[[Distended jugular veins]]
The presence of [finding(s)] on physical examination is highly suggestive of [disease name].
**[[Lower extremity edema]] and/or [[ascites]]
**[[ventricular filling gallop]] [[(S3)]] and/or [[atrial gallop]] [[(S4)]] on [[cardiac auscultation]]


===Laboratory Findings===
===Laboratory Findings===


*Cardiac Troponins:
*[[Cardiac Troponins]]: <ref name="pmid208639502">{{cite journal| author=Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM| title=Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. | journal=J Am Coll Cardiol | year= 2010 | volume= 56 | issue= 14 | pages= 1071-8 | pmid=20863950 | doi=10.1016/j.jacc.2010.06.016 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20863950  }}</ref>
**Elevated cardiac troponin levels suggest the presence of myocardial cell injury or death.
**Elevated [[cardiac troponin]] levels suggest the presence of myocardial cell injury or death.
**Cardiac troponin levels may increase in patients with chronic or acute decompensated HF.<ref name="pmid20863950">{{Cite pmid|20863950}}</ref>
**[[Cardiac troponin]] levels may increase in patients with chronic or acute decompensated [[heart failure]].


*Natriuretic Peptides:
*[[Natriuretic Peptides]]: <ref name="pmid280626282">{{cite journal| author=Saenger AK, Rodriguez-Fraga O, Ler R, Ordonez-Llanos J, Jaffe AS, Goetze JP | display-authors=etal| title=Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides. | journal=Clin Chem | year= 2017 | volume= 63 | issue= 1 | pages= 351-358 | pmid=28062628 | doi=10.1373/clinchem.2016.263749 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28062628 }}</ref> <ref name="pmid322934492">{{cite journal| author=Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B | display-authors=etal| title=Prognostic value of NT-proBNP in patients with severe COVID-19. | journal=Respir Res | year= 2020 | volume= 21 | issue= 1 | pages= 83 | pmid=32293449 | doi=10.1186/s12931-020-01352-w | pmc=7156898 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32293449 }}</ref> <ref name="pmid322329792">{{cite journal| author=Han H, Xie L, Liu R, Yang J, Liu F, Wu K | display-authors=etal| title=Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. | journal=J Med Virol | year= 2020 | volume= 92 | issue= 7 | pages= 819-823 | pmid=32232979 | doi=10.1002/jmv.25809 | pmc=7228305 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32232979 }}</ref> <ref name="pmid18298480">{{cite journal |vauthors=Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, Bingisser R, Miedinger D, Leuppi J, Tamm M, Mueller B, Mueller C |title=Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia |journal=J. Intern. Med. |volume=264 |issue=2 |pages=166–76 |date=August 2008 |pmid=18298480 |doi=10.1111/j.1365-2796.2008.01934.x |url=}}</ref> <ref name="pmid16442916">{{cite journal |vauthors=Mueller C, Laule-Kilian K, Frana B, Rodriguez D, Scholer A, Schindler C, Perruchoud AP |title=Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease |journal=Am. Heart J. |volume=151 |issue=2 |pages=471–7 |date=February 2006 |pmid=16442916 |doi=10.1016/j.ahj.2005.03.036 |url=}}</ref> <ref name="pmid28322314">{{cite journal |vauthors=Lai CC, Sung MI, Ho CH, Liu HH, Chen CM, Chiang SR, Chao CM, Liu WL, Hsing SC, Cheng KC |title=The prognostic value of N-terminal proB-type natriuretic peptide in patients with acute respiratory distress syndrome |journal=Sci Rep |volume=7 |issue= |pages=44784 |date=March 2017 |pmid=28322314 |doi=10.1038/srep44784 |url=}}</ref> <ref name="pmid23837838">{{cite journal |vauthors=Determann RM, Royakkers AA, Schaefers J, de Boer AM, Binnekade JM, van Straalen JP, Schultz MJ |title=Serum levels of N-terminal proB-type natriuretic peptide in mechanically ventilated critically ill patients--relation to tidal volume size and development of acute respiratory distress syndrome |journal=BMC Pulm Med |volume=13 |issue= |pages=42 |date=July 2013 |pmid=23837838 |doi=10.1186/1471-2466-13-42 |url=}}</ref> <ref name="pmid21478812">{{cite journal |vauthors=Park BH, Park MS, Kim YS, Kim SK, Kang YA, Jung JY, Lim JE, Kim EY, Chang J |title=Prognostic utility of changes in N-terminal pro-brain natriuretic Peptide combined with sequential organ failure assessment scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock |journal=Shock |volume=36 |issue=2 |pages=109–14 |date=August 2011 |pmid=21478812 |doi=10.1097/SHK.0b013e31821d8f2d |url=}}</ref>
**Natriuretic peptides (BNP/NT-proBNP) are released from the heart in response to increased myocardial stress and are quantitative markers of increased intracardiac filling pressure.<ref name="pmid28062628">{{Cite pmid|28062628}}</ref>
**[[Natriuretic peptides]] (BNP/NT-proBNP) are released from the heart in response to increased [[myocardial stress]] and are quantitative markers of increased [[intracardiac filling pressure]].
**Elevated BNP and NT-proBNP are of both diagnostic and prognostic significance in patients with heart failure.
**Elevated [[BNP]] and [[NT-proBNP]] are of both diagnostic and prognostic significance in patients with [[heart failure]].
**Increased BNP or NT-proBNP levels have been demonstrated in COVID-19 patients.
**Increased [[BNP]] or [[NT-proBNP]] levels have been demonstrated in COVID-19 patients.
**Increased NT-proBNP level was associated with worse clinical outcomes in patients with severe COVID-19.<ref name="pmid32293449">{{Cite pmid|32293449}}</ref> <ref name="pmid32232979">{{Cite pmid|32232979}}</ref>
**Increased [[NT-proBNP]] level was associated with worse clinical outcomes in patients with severe COVID-19.
**However, increased natriuretic peptide levels are frequently seen among patients with severe inflammatory or respiratory diseases.<ref name="pmid18298480">{{Cite pmid|18298480}}</ref> <ref name="pmid16442916">{{Cite pmid|16442916}}</ref> <ref name="pmid28322314">{{Cite pmid|28322314}}</ref> <ref name="pmid23837838">{{Cite pmid|23837838}}</ref> <ref name="pmid21478812">{{Cite pmid|21478812}}</ref>
**However, increased [[natriuretic peptide]] levels are frequently seen among patients with severe inflammatory or respiratory diseases.
**Therefore, routine measurement of BNP/NT-proBNP has not been recommended in COVID-19 patients, unless there is a high suspicion of HF based on clinical grounds.
**Therefore, routine measurement of [[BNP]]/[[NT-proBNP]] has not been recommended in [[COVID-19 patients]], unless there is a high suspicion of [[heart failure]] based on clinical grounds.


===Electrocardiogram===
===Electrocardiogram===


*There is no specific electrocardiographic finding for acute heart failure in COVID-19 patients.  
*There is no specific electrocardiographic finding for [[acute heart failure]] in [[COVID-19]] patients.  
*The ECG may help in identifying preexisting cardiac abnormalities and precipitating factors, such as ischemia, myocarditis, and arrhythmias.  
*The ECG may help in identifying preexisting cardiac abnormalities and precipitating factors, such as [[ischemia]], [[myocarditis]], and [[arrhythmias]].  
*These ECG findings may include:
*These [[ECG]] findings may include:
**Low QRS Voltage
**[[Low QRS Voltage]]
**Left ventricular hypertrophy
**[[Left ventricular hypertrophy]]
**Left atrial enlargement
**Left atrial enlargement
**Left bundle branch block
**[[Left bundle branch block]]
**Poor R progression
**[[Poor R progression]]
**ST-T changes
**[[Nonspecific ST-T changes]]


===X-ray===
===X-ray===


An x-ray may be helpful in the diagnosis of heart failure. Findings on an x-ray suggestive of heart failure include:
*A [[Chest x-ray]] may be helpful in the diagnosis of [[heart failure]]. Findings on [[chest X-ray]] suggestive of [[heart failure]] include:
**Cardiomegaly  
**[[Cardiomegaly]]
**Pulmonary congestion  
**[[Pulmonary congestion]]
**Increased pulmonary vascular markings.
**Increased pulmonary vascular markings.


*However, signs of pulmonary edema may be obscured by underlying respiratory involvement and ARDS due to COVID-19.
*However, signs of [[pulmonary edema]] may be obscured by underlying respiratory involvement and [[acute respiratory distress syndrome]] due to [[COVID-19]].


===Echocardiography or Ultrasound===
===Echocardiography or Ultrasound===


*A complete standard transthoracic (TTE) has not been recommended in COVID-19 patients considering the limited personal protective equipment (PPE) and the risk of exposure of additional health care personnel.<ref name="pmid32391912">{{Cite pmid|32391912}}</ref>
*A complete standard [[transthoracicechocardiography]] [[(TTE)]] has not been recommended in [[COVID-19]] patients considering the limited [[personal protective equipment (PPE)]] and the risk of exposure of additional health care personnel.<ref name="pmid32391912">{{cite journal |vauthors=Cosyns B, Lochy S, Luchian ML, Gimelli A, Pontone G, Allard SD, de Mey J, Rosseel P, Dweck M, Petersen SE, Edvardsen T |title=The role of cardiovascular imaging for myocardial injury in hospitalized COVID-19 patients |journal=Eur Heart J Cardiovasc Imaging |volume=21 |issue=7 |pages=709–714 |date=July 2020 |pmid=32391912 |doi=10.1093/ehjci/jeaa136 |url=}}</ref>
*To deal with limited resources (both personal protective equipment and personnel) and reducing the exposure time of personnel, a focused TTE to find gross abnormalities in cardiac structure/function seems satisfactory.  
*To deal with limited resources (both [[personal protective equipment]] and personnel) and reducing the exposure time of personnel, a focused [[TTE]] to find gross abnormalities in cardiac structure/function seems satisfactory.  
*In addition, bedside options, which may be performed by the trained personnel who might already be in the room with these patients, might also be considered. These include:
*In addition, bedside options, which may be performed by the trained personnel who might already be in the room with these patients, might also be considered. These include:
**Cardiac point-of-care ultrasound (POCUS)  
**[[Cardiac point-of-care ultrasound]] [[(POCUS)]]
**Focused cardiac ultrasound study (FoCUS)  
**[[Focused cardiac ultrasound study]] [[(FoCUS)]]
**Critical care echocardiography  
**[[Critical care echocardiography]]
 
*Cardiac ultrasound can help in assessing the following parameters:
*Cardiac ultrasound can help in assessing the following parameters:
**Left ventricular systolic function (ejection fraction) to distinguish systolic dysfunction with a reduced ejection fraction (<40%) from diastolic dysfunction with a preserved ejection fraction.
**[[Left ventricular systolic function]] [[(left ventricular ejection fraction, LVEF)]] to distinguish [[systolic dysfunction]] with a [[reduced ejection fraction]] (LVEF<40%) from [[diastolic dysfunction]] with a preserved ejection fraction (LVEF>40%)
**Left ventricular diastolic function
**Left ventricular [[diastolic function]]
**Left ventricular structural abnormalities, including LV size and LV wall thickness
**Left ventricular structural abnormalities, including [[left ventricular size]] and [[left ventricular wall thickness]]
**Left atrial size
**[[Left atrial size]]
**Right ventricular size and function
**[[Right ventricular]] size and function
**Detection and quantification of valvular abnormalities
**Detection and quantification of [[valvular abnormalities]]
**Measurement of systolic pulmonary artery pressure
**Measurement of [[systolic pulmonary artery pressure]]
**Detection and quantification of pericardial effusion
**Detection and quantification of [[pericardial effusion]]
**Detection of regional wall motion abnormalities/reduced strain that would suggest underlying ischemia.
**Detection of [[regional wall motion abnormalities]]/reduced [[strain]] that would suggest underlying [[ischemia]].


===CT scan===
===CT scan===
There are no CT scan findings associated with [disease name].
OR
[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
===MRI===
There are no MRI findings associated with [disease name].
OR
[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].


OR
*A [[Chest CT scan]] may be helpful in the diagnosis of [[pulmonary edema]] in patients with [[heart failure]].
 
*Findings suggestive of [[pulmonary edema]] include:
There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
**[[Interstitial Edema]]:
***[[Gound-glass opacification]]
***Bronchovascular bundle thickening caused by increased vascular diameter and/or peribronchovascular thickening
***[[Interlobular septal thickening]]
**[[Alveolar edema]]:
***[[Airspace consolidation]] (in addition to findings of [[interstitial edema]]).
*In patients with [[cardiogenic pulmonary edema]], caused by increased pulmonary vasculature hydrostatic pressure, bilateral [[pleural effusions]] are also frequently seen.
===CMR===


*Due to the risk of contamination of equipment and staff, performing [[Cardiac magnetic resonance]] [[(CMR)]] should be limited to clinically urgent cases.
*[[Cardiac magnetic resonance]] may be helpful in patients suspicious of [[acute myocarditis]], in particular when elevated [[cardiac biomarkers]], ventricular dysfunction and/or severe [[arrhythmias]] cannot be explained by other diagnostics and imaging studies.
*To read more on the role of CMR in the diagnosis of [[myocarditis]], [[Myocarditis MRI|click here]].<br />
===Other Imaging Findings===
===Other Imaging Findings===
There are no other imaging findings associated with [disease name].
* To view other imaging findings on COVID-19, [[COVID-19 other imaging findings|click here]].<br />
===Other Diagnostic Studies===
* To view other diagnostic studies for COVID-19, [[COVID-19 other diagnostic studies|click here]].<br />


OR
==Treatment==
 
===Medical Therapy===
[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].


===Other Diagnostic Studies===
*[[Acute heart failure]] in the setting of [[COVID-19]] is generally treated similarly to [[acute heart failure]] in other settings. These may include:
There are no other diagnostic studies associated with [disease name].
**[[Fluid restriction]]
**[[Diuretic]] therapy
**[[Vasopressors]] and/or [[inotropes]]
*[[Beta-blockers]] should not be initiated during the acute stage due to their [[negative inotropic effects]].<ref name="pmid24251454">{{cite journal |vauthors=Teerlink JR, Alburikan K, Metra M, Rodgers JE |title=Acute decompensated heart failure update |journal=Curr Cardiol Rev |volume=11 |issue=1 |pages=53–62 |date=2015 |pmid=24251454 |doi=10.2174/1573403x09666131117174414 |url=}}</ref>


OR
*Patients with [[chronic heart failure]] are recommended to continue their previous guideline-directed medical therapy, including [[beta-blockers]], [[ACE inhibitors]] or [[Angiotensin II receptor blockers]], and [[mineralocorticoid receptor antagonists]]. <ref name="pmid31129923">{{cite journal |vauthors=Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS |title=Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology |journal=Eur. J. Heart Fail. |volume=21 |issue=10 |pages=1169–1186 |date=October 2019 |pmid=31129923 |doi=10.1002/ejhf.1531 |url=}}</ref>


[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
===Interventional therapy===
*[[Extracorporeal membrane oxygenation (ECMO)]] may be helpful in patients with [[cardiogenic shock]] unresponsive to medical therapy.


OR
===Surgery===
*The mainstay of treatment for [[acute heart failure]] is medical therapy.
*[[Ventricular assisted devices]] are usually reserved for patients with [[cardiogenic shock]].


Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].
===Primary Prevention===
 
*There are no established measures for the [[primary prevention]] of [[heart failure]] in patients with [[COVID-19]].
==Treatment==
===Medical Therapy===


*Acute heart failure in the setting of COVID-19 is generally treated similarly to acute heart failure in other settings. These may include:
===Secondary Prevention===
**Fluid restriction
*During fluid management in [[heart failure]] patients, attempts would be done to prevent both [[volume overload]] and circulatory failure.
**Diuretic therapy
*[[Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)]] should be used with caution in patients with [[acute heart failure]] due to their effect on fluid and sodium retention.<ref name="pmid12656651">{{cite journal |vauthors=Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH |title=Nonsteroidal anti-inflammatory drugs and heart failure |journal=Drugs |volume=63 |issue=6 |pages=525–34 |date=2003 |pmid=12656651 |doi=10.2165/00003495-200363060-00001 |url=}}</ref>
**Vasopressors and/or inotropes
**Ventricular assisted devices and extracorporeal membrane oxygenation (ECMO)
*Beta-blockers should not be initiated during the acute stage due to their negative inotropic effects.<ref name="pmid24251454">{{Cite pmid|24251454}}</ref>
*Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) should be used with caution in patients with acute heart failure due to their effect on fluid and sodium retention.<ref name="pmid12656651">{{Cite pmid|12656651}}</ref>
*Patients with chronic heart failure are recommended to continue their previous guideline-directed medical therapy, including beta-blockers, ACEI or ARB, and mineralocorticoid receptor antagonists. <ref name="pmid31129923">{{Cite pmid|31129923}}</ref>


==References==
==References==

Latest revision as of 17:25, 23 March 2022

WikiDoc Resources for COVID-19-associated heart failure

Articles

Most recent articles on COVID-19-associated heart failure

Most cited articles on COVID-19-associated heart failure

Review articles on COVID-19-associated heart failure

Articles on COVID-19-associated heart failure in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on COVID-19-associated heart failure

Images of COVID-19-associated heart failure

Photos of COVID-19-associated heart failure

Podcasts & MP3s on COVID-19-associated heart failure

Videos on COVID-19-associated heart failure

Evidence Based Medicine

Cochrane Collaboration on COVID-19-associated heart failure

Bandolier on COVID-19-associated heart failure

TRIP on COVID-19-associated heart failure

Clinical Trials

Ongoing Trials on COVID-19-associated heart failure at Clinical Trials.gov

Trial results on COVID-19-associated heart failure

Clinical Trials on COVID-19-associated heart failure at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on COVID-19-associated heart failure

NICE Guidance on COVID-19-associated heart failure

NHS PRODIGY Guidance

FDA on COVID-19-associated heart failure

CDC on COVID-19-associated heart failure

Books

Books on COVID-19-associated heart failure

News

COVID-19-associated heart failure in the news

Be alerted to news on COVID-19-associated heart failure

News trends on COVID-19-associated heart failure

Commentary

Blogs on COVID-19-associated heart failure

Definitions

Definitions of COVID-19-associated heart failure

Patient Resources / Community

Patient resources on COVID-19-associated heart failure

Discussion groups on COVID-19-associated heart failure

Patient Handouts on COVID-19-associated heart failure

Directions to Hospitals Treating COVID-19-associated heart failure

Risk calculators and risk factors for COVID-19-associated heart failure

Healthcare Provider Resources

Symptoms of COVID-19-associated heart failure

Causes & Risk Factors for COVID-19-associated heart failure

Diagnostic studies for COVID-19-associated heart failure

Treatment of COVID-19-associated heart failure

Continuing Medical Education (CME)

CME Programs on COVID-19-associated heart failure

International

COVID-19-associated heart failure en Espanol

COVID-19-associated heart failure en Francais

Business

COVID-19-associated heart failure in the Marketplace

Patents on COVID-19-associated heart failure

Experimental / Informatics

List of terms related to COVID-19-associated heart failure

Main article: COVID-19

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mitra Chitsazan, M.D.[2]Mandana Chitsazan, M.D. [3]

Synonyms and keywords: Novel coronavirus, COVID-19, Wuhan coronavirus, coronavirus disease-19, coronavirus disease 2019, SARS-CoV-2, 2019-nCoV, 2019 novel coronavirus, heart failure, acute heart failure, de Novo acute heart failure, chronic heart failure, acute decompensated heart failure, HFrEF, HFpEF, heart failure with reduced ejection fraction, heart failure with a preserved ejection fraction

Overview

Both de novo acute heart failure and acute decompensation of chronic heart failure can occur in patients with COVID-19. Patients with chronic heart failure may be at higher risk of developing severe COVID-19 infection due to advanced age and the presence of multiple comorbidities.

Historical perspective

  • In late December 2019, the novel coronavirus, SARS-CoV-2, originated in Wuhan, China. [1]
  • The World Health Organization(WHO) declared the outbreak a Public Health Emergency of International Concern On January 30, 2020, [2] and a pandemic on March 12, 2020. [3]
  • On March 27, 2020, Inciardi et al. reported the first case of acute myopericarditis complicated by heart failure in an otherwise healthy 53-year-old woman one week after the onset of symptoms of COVID-19. [4]

Classification

  • Acute heart failure has two forms:
    • Newly-arisen (“de novo”) acute heart failure
    • Acutely decompensated chronic heart failure (ADCHF)

Pathophysiology



Common Precipitating factors in COVID-19 patients
Cardiac
Pressure overload
Volume overload
  • Renal dysfunction
Pulmonary
Increased systemic metabolic demand
Iatrogenic
  • Cardiovascular toxicity of medications
  • Aggressive fluid resuscitation
Others
  • Anemia

Causes

Acute heart failure in COVID-19 patients may be caused by: [10] [11]

Differentiating COVID-19 associated heart failure from other Diseases

  • For further information about the differential diagnosis, click here.

Epidemiology and Demographics

Age

Gender

Race

Risk Factors

To read more on the risk factors of congestive heart failure, click here.

Screening

  • There is insufficient evidence to recommend routine screening for heart failure in COVID-19 patients.
  • Routine measurement of natriuretic peptides and/or cardiac troponins has not been recommended in the absence of a high index of suspicion for heart failure on the clinical grounds.

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT scan

CMR

Other Imaging Findings

  • To view other imaging findings on COVID-19, click here.

Other Diagnostic Studies

  • To view other diagnostic studies for COVID-19, click here.

Treatment

Medical Therapy

Interventional therapy

Surgery

Primary Prevention

Secondary Prevention

References

  1. ↑ "WHO | Pneumonia of unknown cause – China".
  2. ↑ "Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)".
  3. ↑ "WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020".
  4. ↑ Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, Cani DS, Cerini M, Farina D, Gavazzi E, Maroldi R, Adamo M, Ammirati E, Sinagra G, Lombardi CM, Metra M (March 2020). "Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)". JAMA Cardiol. doi:10.1001/jamacardio.2020.1096. PMID 32219357 Check |pmid= value (help).
  5. ↑ Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D; et al. (2020). "Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)". JAMA Cardiol. doi:10.1001/jamacardio.2020.1096. PMID 32219357 Check |pmid= value (help).
  6. ↑ Mehra MR, Ruschitzka F (2020). "COVID-19 Illness and Heart Failure: A Missing Link?". JACC Heart Fail. 8 (6): 512–514. doi:10.1016/j.jchf.2020.03.004. PMID 32360242 Check |pmid= value (help).
  7. ↑ Xiong TY, Redwood S, Prendergast B, Chen M (2020). "Coronaviruses and the cardiovascular system: acute and long-term implications". Eur Heart J. 41 (19): 1798–1800. doi:10.1093/eurheartj/ehaa231. PMID 32186331 Check |pmid= value (help).
  8. ↑ Musher DM, Abers MS, Corrales-Medina VF (2019). "Acute Infection and Myocardial Infarction". N Engl J Med. 380 (2): 171–176. doi:10.1056/NEJMra1808137. PMID 30625066.
  9. ↑ Chen C, Zhou Y, Wang DW (2020). "SARS-CoV-2: a potential novel etiology of fulminant myocarditis". Herz. 45 (3): 230–232. doi:10.1007/s00059-020-04909-z. PMC 7080076 Check |pmc= value (help). PMID 32140732 Check |pmid= value (help).
  10. ↑ 10.0 10.1 Jabri A, Kalra A, Kumar A, Alameh A, Adroja S, Bashir H, Nowacki AS, Shah R, Khubber S, Kanaa'N A, Hedrick DP, Sleik KM, Mehta N, Chung MK, Khot UN, Kapadia SR, Puri R, Reed GW (July 2020). "Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic". JAMA Netw Open. 3 (7): e2014780. doi:10.1001/jamanetworkopen.2020.14780. PMC 7348683 Check |pmc= value (help). PMID 32644140 Check |pmid= value (help).
  11. ↑ 11.0 11.1 Minhas AS, Scheel P, Garibaldi B, Liu G, Horton M, Jennings M, Jones SR, Michos ED, Hays AG (May 2020). "Takotsubo Syndrome in the Setting of COVID-19 Infection". JACC Case Rep. doi:10.1016/j.jaccas.2020.04.023. PMC 7194596 Check |pmc= value (help). PMID 32363351 Check |pmid= value (help).
  12. ↑ [+https://doi.org/10.1001/jamacardio.2020.0950 "Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China | Global Health | JAMA Cardiology | JAMA Network"] Check |url= value (help).
  13. ↑ Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (March 2020). "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study". Lancet. 395 (10229): 1054–1062. doi:10.1016/S0140-6736(20)30566-3. PMC 7270627 Check |pmc= value (help). PMID 32171076 Check |pmid= value (help).
  14. ↑ Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM (2010). "Troponin elevation in heart failure prevalence, mechanisms, and clinical implications". J Am Coll Cardiol. 56 (14): 1071–8. doi:10.1016/j.jacc.2010.06.016. PMID 20863950.
  15. ↑ Saenger AK, Rodriguez-Fraga O, Ler R, Ordonez-Llanos J, Jaffe AS, Goetze JP; et al. (2017). "Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides". Clin Chem. 63 (1): 351–358. doi:10.1373/clinchem.2016.263749. PMID 28062628.
  16. ↑ Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B; et al. (2020). "Prognostic value of NT-proBNP in patients with severe COVID-19". Respir Res. 21 (1): 83. doi:10.1186/s12931-020-01352-w. PMC 7156898 Check |pmc= value (help). PMID 32293449 Check |pmid= value (help).
  17. ↑ Han H, Xie L, Liu R, Yang J, Liu F, Wu K; et al. (2020). "Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China". J Med Virol. 92 (7): 819–823. doi:10.1002/jmv.25809. PMC 7228305 Check |pmc= value (help). PMID 32232979 Check |pmid= value (help).
  18. ↑ Christ-Crain M, Breidthardt T, Stolz D, Zobrist K, Bingisser R, Miedinger D, Leuppi J, Tamm M, Mueller B, Mueller C (August 2008). "Use of B-type natriuretic peptide in the risk stratification of community-acquired pneumonia". J. Intern. Med. 264 (2): 166–76. doi:10.1111/j.1365-2796.2008.01934.x. PMID 18298480.
  19. ↑ Mueller C, Laule-Kilian K, Frana B, Rodriguez D, Scholer A, Schindler C, Perruchoud AP (February 2006). "Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease". Am. Heart J. 151 (2): 471–7. doi:10.1016/j.ahj.2005.03.036. PMID 16442916.
  20. ↑ Lai CC, Sung MI, Ho CH, Liu HH, Chen CM, Chiang SR, Chao CM, Liu WL, Hsing SC, Cheng KC (March 2017). "The prognostic value of N-terminal proB-type natriuretic peptide in patients with acute respiratory distress syndrome". Sci Rep. 7: 44784. doi:10.1038/srep44784. PMID 28322314.
  21. ↑ Determann RM, Royakkers AA, Schaefers J, de Boer AM, Binnekade JM, van Straalen JP, Schultz MJ (July 2013). "Serum levels of N-terminal proB-type natriuretic peptide in mechanically ventilated critically ill patients--relation to tidal volume size and development of acute respiratory distress syndrome". BMC Pulm Med. 13: 42. doi:10.1186/1471-2466-13-42. PMID 23837838.
  22. ↑ Park BH, Park MS, Kim YS, Kim SK, Kang YA, Jung JY, Lim JE, Kim EY, Chang J (August 2011). "Prognostic utility of changes in N-terminal pro-brain natriuretic Peptide combined with sequential organ failure assessment scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock". Shock. 36 (2): 109–14. doi:10.1097/SHK.0b013e31821d8f2d. PMID 21478812.
  23. ↑ Cosyns B, Lochy S, Luchian ML, Gimelli A, Pontone G, Allard SD, de Mey J, Rosseel P, Dweck M, Petersen SE, Edvardsen T (July 2020). "The role of cardiovascular imaging for myocardial injury in hospitalized COVID-19 patients". Eur Heart J Cardiovasc Imaging. 21 (7): 709–714. doi:10.1093/ehjci/jeaa136. PMID 32391912 Check |pmid= value (help).
  24. ↑ Teerlink JR, Alburikan K, Metra M, Rodgers JE (2015). "Acute decompensated heart failure update". Curr Cardiol Rev. 11 (1): 53–62. doi:10.2174/1573403x09666131117174414. PMID 24251454.
  25. ↑ Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland J, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats A (October 2019). "Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology". Eur. J. Heart Fail. 21 (10): 1169–1186. doi:10.1002/ejhf.1531. PMID 31129923. Vancouver style error: initials (help)
  26. ↑ Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH (2003). "Nonsteroidal anti-inflammatory drugs and heart failure". Drugs. 63 (6): 525–34. doi:10.2165/00003495-200363060-00001. PMID 12656651.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=COVID-19-associated_heart_failure&oldid=1721361"